Shares of Stoke Therapeutics, Inc. STOK surged in today’s
pre-market trading following the announcement of Phase 1/2a data supporting the potential for STK-001 in
Dravet syndrome.
Stoke Therapeutics shares skyrocketed by 69.7% to $11.03 in pre-market trading.
Exploring other stocks experiencing movement in pre-market trading reveals some
compelling shifts.
Winners
- Check-Cap Ltd. CHEK witnessed a 38.3% rise to $2.67 in pre-market trading
after Nobul AI Corp entered into a business combination agreement with Check-Cap. - C3is Inc. CISS climbed 35.2% to $0.0476 in pre-market trading with
the anticipation of releasing fourth-quarter financial results. - OpGen, Inc. OPGN experienced a 30.4% increase to $0.6196 driven by a $3
million investment by David Lazar and the appointment of a new CEO. - Mesoblast Limited MESO saw a 23.2% hike to $2.71 following FDA
acknowledgment of sufficient clinical data. - Intelligent Group Limited INTJ rose by 19.7% to $2.31 in pre-market trading, rebounding from a 9% dip the previous day.
Losers
- NeuBase Therapeutics, Inc. NBSE plummeted by 54.5% to $0.4497 in pre-market trading.
- AppTech Payments Corp. APCX dropped 35.8% to $1.06 following a proposed underwritten public offering of common stock.
- Tivic Health Systems, Inc. TIVC fell 20% to $1.16 after announcing fourth-quarter results.
- BuzzFeed, Inc. BZFD declined 12.5% to $0.3530 after disappointing fourth-quarter results and a cautious outlook.
- Vivakor, Inc. VIVK fell by 12.2% to $0.7285 in pre-market trading after announcing an acquisition deal.
Now Read This: Cramer Isn’t ‘Knocking’ This Pharma Firm Anymore: ‘As A Matter
Of Fact, I’m Going In’
